Details for New Drug Application (NDA): 207797
✉ Email this page to a colleague
The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.
Summary for 207797
| Tradename: | RIVASTIGMINE TARTRATE |
| Applicant: | Chartwell Rx |
| Ingredient: | rivastigmine tartrate |
| Patents: | 0 |
Pharmacology for NDA: 207797
| Mechanism of Action | Cholinesterase Inhibitors |
Suppliers and Packaging for NDA: 207797
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 207797 | ANDA | Chartwell RX, LLC | 62135-900 | 62135-900-60 | 60 CAPSULE in 1 BOTTLE (62135-900-60) |
| RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 207797 | ANDA | Chartwell RX, LLC | 62135-901 | 62135-901-60 | 60 CAPSULE in 1 BOTTLE (62135-901-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 1.5MG BASE | ||||
| Approval Date: | Sep 28, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 3MG BASE | ||||
| Approval Date: | Sep 28, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 4.5MG BASE | ||||
| Approval Date: | Sep 28, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
